Clinical Trials
19 trialsNCT00263575 2024-06-18
Long-term Safety Study of Sublingual Fentanyl Tablets in Cancer Patients
Kyowa Kirin Co., Ltd.
Phase 3 Completed
NCT04786275 2023-11-27
NoLPedFenta
Pontificia Universidad Catolica de Chile
Completed
NCT02359175 2023-06-27
SEAVATS
Odense University Hospital
Phase 4 Completed
NCT00293033 2019-11-18
Study of BEMAâ„¢ Fentanyl in the Treatment of Breakthrough Pain in Cancer Subjects
BioDelivery Sciences International
Phase 3 Completed
NCT01544959 2018-10-24
PAINFree
Université de Sherbrooke
Phase NA Completed
NCT02684942 2017-06-01
Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy
Chulabhorn Cancer Center
Phase 4 Completed
NCT00003000 2015-10-14
Morphine for the Treatment of Pain in Patients With Breast Cancer
Roswell Park Cancer Institute
Completed
NCT01317589 2015-07-16
310111-4
Maastricht University Medical Center
Phase 4 Completed
NCT00295945 2014-05-20
Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer
University of California, San Francisco
Completed
NCT01248611 2014-05-12
NFCP1-2010
St. Olavs Hospital
Phase 1/2 Completed
NCT00236093 2014-05-09
Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Completed
NCT00538850 2014-03-05
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
INSYS Therapeutics Inc
Phase 3 Completed
NCT00458510 2013-07-11
Long Term Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain
Archimedes Development Ltd
Phase 3 Completed
NCT00644787 2013-06-13
A Dose-Finding Study of Fentanyl (JNS020 QD) 1-Day Transdermal Patch in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 2/3 Completed
NCT00641667 2013-06-07
An Efficacy and Safety Study of Fentanyl (JNS020QD) in Participants With Cancer Pain
Janssen Pharmaceutical K.K.
Phase 3 Completed
NCT00355628 2012-08-31
Clinical Study of KW-2246 in Patients With Cancer Pain
Kyowa Kirin Co., Ltd.
Phase 2 Completed
NCT00345735 2012-05-07
Intranasal Fentanyl for the Treatment of Breakthrough Pain in Cancer Patients (FT-017-IM)
Nycomed
Phase 2 Completed
NCT00459277 2012-01-25
Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed
NCT00589823 2010-01-22
Efficacy and Safety Study of Nasalfent for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids
Archimedes Development Ltd
Phase 3 Completed